Skip to main content
NCBI home page
Clinical Microbiology Reviews logoLink to Clinical Microbiology Reviews
. 1995 Jul;8(3):427–439. doi: 10.1128/cmr.8.3.427

Human antiprotozoal therapy: past, present, and future.

M Khaw 1, C B Panosian 1
PMCID: PMC174634  PMID: 7553575

Abstract

Human protozoal infections are ubiquitous and occur worldwide. In many cases, antiprotozoal agents currently in use predate the modern antibiotic era. Despite the relative lag in development of new antiprotozoal agents, the 1990s have witnessed an increasing level of interest in these infections, inspired by international travel and immigration, a growing awareness of antiprotozoal drug resistance, and the significance of acute and recrudescent protozoal infections in immunosuppressed hosts. This review summarizes for nonclinician readers the past, present, and future therapies for common human protozoal infections, as well as pharmacologic mechanisms of action and resistance and common toxicities associated with these agents.

Full Text

The Full Text of this article is available as a PDF (254.7 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abaru D. E., Liwo D. A., Isakina D., Okori E. E. Retrospective long-term study of effects of berenil by follow-up of patients treated since 1965. Tropenmed Parasitol. 1984 Sep;35(3):148–150. [PubMed] [Google Scholar]
  2. Andrade S. G., Rassi A., Magalhaes J. B., Ferriolli Filho F., Luquetti A. O. Specific chemotherapy of Chagas disease: a comparison between the response in patients and experimental animals inoculated with the same strains. Trans R Soc Trop Med Hyg. 1992 Nov-Dec;86(6):624–626. doi: 10.1016/0035-9203(92)90156-7. [DOI] [PubMed] [Google Scholar]
  3. Appleman M. D., Shulman I. A., Saxena S., Kirchhoff L. V. Use of a questionnaire to identify potential blood donors at risk for infection with Trypanosoma cruzi. Transfusion. 1993 Jan;33(1):61–64. doi: 10.1046/j.1537-2995.1993.33193142312.x. [DOI] [PubMed] [Google Scholar]
  4. Araujo F. G., Guptill D. R., Remington J. S. Azithromycin, a macrolide antibiotic with potent activity against Toxoplasma gondii. Antimicrob Agents Chemother. 1988 May;32(5):755–757. doi: 10.1128/aac.32.5.755. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Araujo F. G., Guptill D. R., Remington J. S. In vivo activity of piritrexim [corrected] against Toxoplasma gondii. J Infect Dis. 1987 Nov;156(5):828–830. doi: 10.1093/infdis/156.5.828. [DOI] [PubMed] [Google Scholar]
  6. Araujo F. G., Huskinson-Mark J., Gutteridge W. E., Remington J. S. In vitro and in vivo activities of the hydroxynaphthoquinone 566C80 against the cyst form of Toxoplasma gondii. Antimicrob Agents Chemother. 1992 Feb;36(2):326–330. doi: 10.1128/aac.36.2.326. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Armitage K., Flanigan T., Carey J., Frank I., MacGregor R. R., Ross P., Goodgame R., Turner J. Treatment of cryptosporidiosis with paromomycin. A report of five cases. Arch Intern Med. 1992 Dec;152(12):2497–2499. [PubMed] [Google Scholar]
  8. Arrowood M. J., Jaynes J. M., Healey M. C. Hemolytic properties of lytic peptides active against the sporozoites of Cryptosporidium parvum. J Protozool. 1991 Nov-Dec;38(6):161S–163S. [PubMed] [Google Scholar]
  9. Arroz J. O. Melarsoprol and reactive encephalopathy in Trypanosoma brucei rhodesiense. Trans R Soc Trop Med Hyg. 1987;81(2):192–192. doi: 10.1016/0035-9203(87)90211-2. [DOI] [PubMed] [Google Scholar]
  10. Aucott J. N., Ravdin J. I. Amebiasis and "nonpathogenic" intestinal protozoa. Infect Dis Clin North Am. 1993 Sep;7(3):467–485. [PubMed] [Google Scholar]
  11. Avila J. L., Avila A. Trypanosoma cruzi: allopurinol in the treatment of mice with experimental acute Chagas disease. Exp Parasitol. 1981 Apr;51(2):204–208. doi: 10.1016/0014-4894(81)90109-0. [DOI] [PubMed] [Google Scholar]
  12. Bacchi C. J., Nathan H. C., Livingston T., Valladares G., Saric M., Sayer P. D., Njogu A. R., Clarkson A. B., Jr Differential susceptibility to DL-alpha-difluoromethylornithine in clinical isolates of Trypanosoma brucei rhodesiense. Antimicrob Agents Chemother. 1990 Jun;34(6):1183–1188. doi: 10.1128/aac.34.6.1183. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Badaro R., Falcoff E., Badaro F. S., Carvalho E. M., Pedral-Sampaio D., Barral A., Carvalho J. S., Barral-Netto M., Brandely M., Silva L. Treatment of visceral leishmaniasis with pentavalent antimony and interferon gamma. N Engl J Med. 1990 Jan 4;322(1):16–21. doi: 10.1056/NEJM199001043220104. [DOI] [PubMed] [Google Scholar]
  14. Baird J. K., Basri H., Purnomo, Bangs M. J., Subianto B., Patchen L. C., Hoffman S. L. Resistance to chloroquine by Plasmodium vivax in Irian Jaya, Indonesia. Am J Trop Med Hyg. 1991 May;44(5):547–552. doi: 10.4269/ajtmh.1991.44.547. [DOI] [PubMed] [Google Scholar]
  15. Bartlett J. G., Chang T. W., Gurwith M., Gorbach S. L., Onderdonk A. B. Antibiotic-associated pseudomembranous colitis due to toxin-producing clostridia. N Engl J Med. 1978 Mar 9;298(10):531–534. doi: 10.1056/NEJM197803092981003. [DOI] [PubMed] [Google Scholar]
  16. Beaugerie L., Teilhac M. F., Deluol A. M., Fritsch J., Girard P. M., Rozenbaum W., Le Quintrec Y., Chatelet F. P. Cholangiopathy associated with Microsporidia infection of the common bile duct mucosa in a patient with HIV infection. Ann Intern Med. 1992 Sep 1;117(5):401–402. doi: 10.7326/0003-4819-117-5-401. [DOI] [PubMed] [Google Scholar]
  17. Blanshard C., Ellis D. S., Dowell S. P., Tovey G., Gazzard B. G. Electron microscopic changes in Enterocytozoon bieneusi following treatment with albendazole. J Clin Pathol. 1993 Oct;46(10):898–902. doi: 10.1136/jcp.46.10.898. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Bryson H. M., Goa K. L. Halofantrine. A review of its antimalarial activity, pharmacokinetic properties and therapeutic potential. Drugs. 1992 Feb;43(2):236–258. doi: 10.2165/00003495-199243020-00009. [DOI] [PubMed] [Google Scholar]
  19. COATNEY G. R., GETZ M. E. Primaquine and quinocide as curative agents against sporozoite-induced Chesson strain vivax malaria. Bull World Health Organ. 1962;27:290–293. [PMC free article] [PubMed] [Google Scholar]
  20. Carr A., Tindall B., Brew B. J., Marriott D. J., Harkness J. L., Penny R., Cooper D. A. Low-dose trimethoprim-sulfamethoxazole prophylaxis for toxoplasmic encephalitis in patients with AIDS. Ann Intern Med. 1992 Jul 15;117(2):106–111. doi: 10.7326/0003-4819-117-2-106. [DOI] [PubMed] [Google Scholar]
  21. Cedeño J. R., Krogstad D. J. Susceptibility testing of Entamoeba histolytica. J Infect Dis. 1983 Dec;148(6):1090–1095. doi: 10.1093/infdis/148.6.1090. [DOI] [PubMed] [Google Scholar]
  22. Chang H. R., Pechere J. C. Effect of roxithromycin on acute toxoplasmosis in mice. Antimicrob Agents Chemother. 1987 Jul;31(7):1147–1149. doi: 10.1128/aac.31.7.1147. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Clotet B., Sirera G., Romeu J., Gimeno J. M., Jou A., Condom M. J., Tor J., Foz M. Twice-weekly dapsone-pyrimethamine for preventing PCP and cerebral toxoplasmosis. AIDS. 1991 May;5(5):601–602. [PubMed] [Google Scholar]
  24. Colwell E. J., Hickman R. L., Intraprasert R., Tirabutana C. Minocycline and tetracycline treatment of acute falciparum malaria in Thailand. Am J Trop Med Hyg. 1972 Mar;21(2):144–149. doi: 10.4269/ajtmh.1972.21.144. [DOI] [PubMed] [Google Scholar]
  25. Craun G. F. Waterborne giardiasis in the United States 1965-84. Lancet. 1986 Aug 30;2(8505):513–514. doi: 10.1016/s0140-6736(86)90382-x. [DOI] [PubMed] [Google Scholar]
  26. Current W. L., Garcia L. S. Cryptosporidiosis. Clin Microbiol Rev. 1991 Jul;4(3):325–358. doi: 10.1128/cmr.4.3.325. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Dannemann B., McCutchan J. A., Israelski D., Antoniskis D., Leport C., Luft B., Nussbaum J., Clumeck N., Morlat P., Chiu J. Treatment of toxoplasmic encephalitis in patients with AIDS. A randomized trial comparing pyrimethamine plus clindamycin to pyrimethamine plus sulfadiazine. The California Collaborative Treatment Group. Ann Intern Med. 1992 Jan 1;116(1):33–43. doi: 10.7326/0003-4819-116-1-33. [DOI] [PubMed] [Google Scholar]
  28. Davidson R. N., Croft S. L. Recent advances in the treatment of visceral leishmaniasis. Trans R Soc Trop Med Hyg. 1993 Mar-Apr;87(2):130-1, 141. doi: 10.1016/0035-9203(93)90457-2. [DOI] [PubMed] [Google Scholar]
  29. Doua F., Boa F. Y., Schechter P. J., Miézan T. W., Diai D., Sanon S. R., De Raadt P., Haegele K. D., Sjoerdsma A., Konian K. Treatment of human late stage gambiense trypanosomiasis with alpha-difluoromethylornithine (eflornithine): efficacy and tolerance in 14 cases in Côte d'Ivoire. Am J Trop Med Hyg. 1987 Nov;37(3):525–533. doi: 10.4269/ajtmh.1987.37.525. [DOI] [PubMed] [Google Scholar]
  30. Edlind T. D., Hang T. L., Chakraborty P. R. Activity of the anthelmintic benzimidazoles against Giardia lamblia in vitro. J Infect Dis. 1990 Dec;162(6):1408–1411. doi: 10.1093/infdis/162.6.1408. [DOI] [PubMed] [Google Scholar]
  31. Fafard J., Lalonde R. Long-standing symptomatic cryptosporidiosis in a normal man: clinical response to spiramycin. J Clin Gastroenterol. 1990 Apr;12(2):190–191. doi: 10.1097/00004836-199004000-00016. [DOI] [PubMed] [Google Scholar]
  32. Fayer R., Ellis W. Glycoside antibiotics alone and combined with tetracyclines for prophylaxis of experimental cryptosporidiosis in neonatal BALB/c mice. J Parasitol. 1993 Aug;79(4):553–558. [PubMed] [Google Scholar]
  33. Fernandez-Martin J., Leport C., Morlat P., Meyohas M. C., Chauvin J. P., Vilde J. L. Pyrimethamine-clarithromycin combination for therapy of acute Toxoplasma encephalitis in patients with AIDS. Antimicrob Agents Chemother. 1991 Oct;35(10):2049–2052. doi: 10.1128/aac.35.10.2049. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Fichtenbaum C. J., Ritchie D. J., Powderly W. G. Use of paromomycin for treatment of cryptosporidiosis in patients with AIDS. Clin Infect Dis. 1993 Feb;16(2):298–300. doi: 10.1093/clind/16.2.298. [DOI] [PubMed] [Google Scholar]
  35. Forestier F., Daffos F., Hohlfeld P., Lynch L. Les foetopathies infectieuses. Prévention, diagnostic prénatal, attitude pratique. Presse Med. 1991 Sep 28;20(30):1448–1454. [PubMed] [Google Scholar]
  36. Francioli P. B., Keithly J. S., Jones T. C., Brandstetter R. D., Wolf D. J. Response of babesiosis to pentamidine therapy. Ann Intern Med. 1981 Mar;94(3):326–330. doi: 10.7326/0003-4819-94-3-326. [DOI] [PubMed] [Google Scholar]
  37. GHOSH M., LEVY P. M., LEOPOLD I. H. THERAPY OF TOXOPLASMOSIS UVEITIS. Am J Ophthalmol. 1965 Jan;59:55–61. doi: 10.1016/0002-9394(65)95020-8. [DOI] [PubMed] [Google Scholar]
  38. Gallerano R. H., Marr J. J., Sosa R. R. Therapeutic efficacy of allopurinol in patients with chronic Chagas' disease. Am J Trop Med Hyg. 1990 Aug;43(2):159–166. doi: 10.4269/ajtmh.1990.43.159. [DOI] [PubMed] [Google Scholar]
  39. Garavelli P. L., Corti E. Chloroquine resistance in Plasmodium vivax: the first case in Brazil. Trans R Soc Trop Med Hyg. 1992 Mar-Apr;86(2):128–128. doi: 10.1016/0035-9203(92)90535-k. [DOI] [PubMed] [Google Scholar]
  40. Girard P. M., Landman R., Gaudebout C., Olivares R., Saimot A. G., Jelazko P., Gaudebout C., Certain A., Boué F., Bouvet E. Dapsone-pyrimethamine compared with aerosolized pentamidine as primary prophylaxis against Pneumocystis carinii pneumonia and toxoplasmosis in HIV infection. The PRIO Study Group. N Engl J Med. 1993 May 27;328(21):1514–1520. doi: 10.1056/NEJM199305273282102. [DOI] [PubMed] [Google Scholar]
  41. Goldberg D. E., Slater A. F., Beavis R., Chait B., Cerami A., Henderson G. B. Hemoglobin degradation in the human malaria pathogen Plasmodium falciparum: a catabolic pathway initiated by a specific aspartic protease. J Exp Med. 1991 Apr 1;173(4):961–969. doi: 10.1084/jem.173.4.961. [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Gorla N. B., Ledesma O. S., Barbieri G. P., Larripa I. B. Thirteenfold increase of chromosomal aberrations non-randomly distributed in chagasic children treated with nifurtimox. Mutat Res. 1989 Oct;224(2):263–267. doi: 10.1016/0165-1218(89)90165-1. [DOI] [PubMed] [Google Scholar]
  43. Grady R. W., Bienen E. J., Dieck H. A., Saric M., Clarkson A. B., Jr N-n-alkyl-3,4-dihydroxybenzamides as inhibitors of the trypanosome alternative oxidase: activity in vitro and in vivo. Antimicrob Agents Chemother. 1993 May;37(5):1082–1085. doi: 10.1128/aac.37.5.1082. [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. Grogl M., Thomason T. N., Franke E. D. Drug resistance in leishmaniasis: its implication in systemic chemotherapy of cutaneous and mucocutaneous disease. Am J Trop Med Hyg. 1992 Jul;47(1):117–126. doi: 10.4269/ajtmh.1992.47.117. [DOI] [PubMed] [Google Scholar]
  45. Grossman P. L., Remington J. S. The effect of trimethoprim and sulfamethoxazole on Toxoplasma gondii in vitro and in vivo. Am J Trop Med Hyg. 1979 May;28(3):445–455. doi: 10.4269/ajtmh.1979.28.445. [DOI] [PubMed] [Google Scholar]
  46. Gutteridge W. E. Existing chemotherapy and its limitations. Br Med Bull. 1985 Apr;41(2):162–168. doi: 10.1093/oxfordjournals.bmb.a072044. [DOI] [PubMed] [Google Scholar]
  47. Gyang F. N., Peterson D. S., Wellems T. E. Plasmodium falciparum: rapid detection of dihydrofolate reductase mutations that confer resistance to cycloguanil and pyrimethamine. Exp Parasitol. 1992 Jun;74(4):470–472. doi: 10.1016/0014-4894(92)90209-s. [DOI] [PubMed] [Google Scholar]
  48. Hall A., Nahar Q. Albendazole as a treatment for infections with Giardia duodenalis in children in Bangladesh. Trans R Soc Trop Med Hyg. 1993 Jan-Feb;87(1):84–86. doi: 10.1016/0035-9203(93)90435-s. [DOI] [PubMed] [Google Scholar]
  49. Harinasuta T., Bunnag D., Lasserre R., Leimer R., Vinijanont S. Trials of mefloquine in vivax and of mefloquine plus 'fansidar' in falciparum malaria. Lancet. 1985 Apr 20;1(8434):885–888. doi: 10.1016/s0140-6736(85)91670-8. [DOI] [PubMed] [Google Scholar]
  50. Haverkos H. W. Assessment of therapy for toxoplasma encephalitis. The TE Study Group. Am J Med. 1987 May;82(5):907–914. doi: 10.1016/0002-9343(87)90151-3. [DOI] [PubMed] [Google Scholar]
  51. Herwaldt B. L., Berman J. D. Recommendations for treating leishmaniasis with sodium stibogluconate (Pentostam) and review of pertinent clinical studies. Am J Trop Med Hyg. 1992 Mar;46(3):296–306. doi: 10.4269/ajtmh.1992.46.296. [DOI] [PubMed] [Google Scholar]
  52. Hien T. T., Arnold K., Vinh H., Cuong B. M., Phu N. H., Chau T. T., Hoa N. T., Chuong L. V., Mai N. T., Vinh N. N. Comparison of artemisinin suppositories with intravenous artesunate and intravenous quinine in the treatment of cerebral malaria. Trans R Soc Trop Med Hyg. 1992 Nov-Dec;86(6):582–583. doi: 10.1016/0035-9203(92)90137-2. [DOI] [PubMed] [Google Scholar]
  53. Hien T. T., White N. J. Qinghaosu. Lancet. 1993 Mar 6;341(8845):603–608. doi: 10.1016/0140-6736(93)90362-k. [DOI] [PubMed] [Google Scholar]
  54. Hoffman S. L., Rustama D., Punjabi N. H., Surampaet B., Sanjaya B., Dimpudus A. J., McKee K. T., Jr, Paleologo F. P., Campbell J. R., Marwoto H. High-dose dexamethasone in quinine-treated patients with cerebral malaria: a double-blind, placebo-controlled trial. J Infect Dis. 1988 Aug;158(2):325–331. doi: 10.1093/infdis/158.2.325. [DOI] [PubMed] [Google Scholar]
  55. Hunter C. A., Jennings F. W., Adams J. H., Murray M., Kennedy P. G. Subcurative chemotherapy and fatal post-treatment reactive encephalopathies in African trypanosomiasis. Lancet. 1992 Apr 18;339(8799):956–958. doi: 10.1016/0140-6736(92)91531-c. [DOI] [PubMed] [Google Scholar]
  56. Huskinson-Mark J., Araujo F. G., Remington J. S. Evaluation of the effect of drugs on the cyst form of Toxoplasma gondii. J Infect Dis. 1991 Jul;164(1):170–171. doi: 10.1093/infdis/164.1.170. [DOI] [PubMed] [Google Scholar]
  57. Jacoby G. A., Hunt J. V., Kosinski K. S., Demirjian Z. N., Huggins C., Etkind P., Marcus L. C., Spielman A. Treatment of transfusion-transmitted babesiosis by exchange transfusion. N Engl J Med. 1980 Nov 6;303(19):1098–1100. doi: 10.1056/NEJM198011063031906. [DOI] [PubMed] [Google Scholar]
  58. Jennings F. W. Combination chemotherapy of CNS trypanosomiasis. Acta Trop. 1993 Sep;54(3-4):205–213. doi: 10.1016/0001-706x(93)90093-q. [DOI] [PubMed] [Google Scholar]
  59. Kirchhoff L. V. Chagas disease. American trypanosomiasis. Infect Dis Clin North Am. 1993 Sep;7(3):487–502. [PubMed] [Google Scholar]
  60. Knight R. The chemotherapy of amoebiasis. J Antimicrob Chemother. 1980 Sep;6(5):577–593. doi: 10.1093/jac/6.5.577. [DOI] [PubMed] [Google Scholar]
  61. Kovacs J. A. Efficacy of atovaquone in treatment of toxoplasmosis in patients with AIDS. The NIAID-Clinical Center Intramural AIDS Program. Lancet. 1992 Sep 12;340(8820):637–638. doi: 10.1016/0140-6736(92)92172-c. [DOI] [PubMed] [Google Scholar]
  62. Kreutner A. K., Del Bene V. E., Amstey M. S. Giardiasis in pregnancy. Am J Obstet Gynecol. 1981 Aug 15;140(8):895–901. doi: 10.1016/0002-9378(81)90082-x. [DOI] [PubMed] [Google Scholar]
  63. Krogstad D. J., Gluzman I. Y., Kyle D. E., Oduola A. M., Martin S. K., Milhous W. K., Schlesinger P. H. Efflux of chloroquine from Plasmodium falciparum: mechanism of chloroquine resistance. Science. 1987 Nov 27;238(4831):1283–1285. doi: 10.1126/science.3317830. [DOI] [PubMed] [Google Scholar]
  64. Laughon B. E., Druckman D. A., Vernon A., Quinn T. C., Polk B. F., Modlin J. F., Yolken R. H., Bartlett J. G. Prevalence of enteric pathogens in homosexual men with and without acquired immunodeficiency syndrome. Gastroenterology. 1988 Apr;94(4):984–993. doi: 10.1016/0016-5085(88)90557-4. [DOI] [PubMed] [Google Scholar]
  65. Leport C., Raffi F., Matheron S., Katlama C., Regnier B., Saimot A. G., Marche C., Vedrenne C., Vilde J. L. Treatment of central nervous system toxoplasmosis with pyrimethamine/sulfadiazine combination in 35 patients with the acquired immunodeficiency syndrome. Efficacy of long-term continuous therapy. Am J Med. 1988 Jan;84(1):94–100. doi: 10.1016/0002-9343(88)90014-9. [DOI] [PubMed] [Google Scholar]
  66. Leport C., Vilde J. L., Katlama C., Regnier B., Matheron S., Saimot A. G. Failure of spiramycin to prevent neurotoxoplasmosis in immunosuppressed patients. JAMA. 1986 May 2;255(17):2290–2290. doi: 10.1001/jama.1986.03370170054013. [DOI] [PubMed] [Google Scholar]
  67. Levi G. C., de Avila C. A., Amato Neto V. Efficacy of various drugs for treatment of giardiasis. A comparative study. Am J Trop Med Hyg. 1977 May;26(3):564–565. doi: 10.4269/ajtmh.1977.26.564. [DOI] [PubMed] [Google Scholar]
  68. Lobel H. O., Bernard K. W., Williams S. L., Hightower A. W., Patchen L. C., Campbell C. C. Effectiveness and tolerance of long-term malaria prophylaxis with mefloquine. Need for a better dosing regimen. JAMA. 1991 Jan 16;265(3):361–364. [PubMed] [Google Scholar]
  69. Lobel H. O., Miani M., Eng T., Bernard K. W., Hightower A. W., Campbell C. C. Long-term malaria prophylaxis with weekly mefloquine. Lancet. 1993 Apr 3;341(8849):848–851. doi: 10.1016/0140-6736(93)93058-9. [DOI] [PubMed] [Google Scholar]
  70. Loiseau P. M., Wolf J. G., Gayral P. Spiroarsoranes of second generation: evaluation of trypanocidal properties against Trypanosoma brucei brucei. Trop Med Parasitol. 1993 Mar;44(1):32–36. [PubMed] [Google Scholar]
  71. Lortholary O., Mechali D., Christiaens D., Gougerot Pocidalo M., Brandely M., Babinet P. Interferon-gamma associated with conventional therapy for recurrent visceral leishmaniasis in a patient with AIDS. Rev Infect Dis. 1990 Mar-Apr;12(2):370–371. doi: 10.1093/clinids/12.2.370. [DOI] [PubMed] [Google Scholar]
  72. Luft B. J., Hafner R., Korzun A. H., Leport C., Antoniskis D., Bosler E. M., Bourland D. D., 3rd, Uttamchandani R., Fuhrer J., Jacobson J. Toxoplasmic encephalitis in patients with the acquired immunodeficiency syndrome. Members of the ACTG 077p/ANRS 009 Study Team. N Engl J Med. 1993 Sep 30;329(14):995–1000. doi: 10.1056/NEJM199309303291403. [DOI] [PubMed] [Google Scholar]
  73. Luft B. J., Remington J. S. Toxoplasmic encephalitis in AIDS. Clin Infect Dis. 1992 Aug;15(2):211–222. doi: 10.1093/clinids/15.2.211. [DOI] [PubMed] [Google Scholar]
  74. Machtinger L., Telford S. R., 3rd, Inducil C., Klapper E., Pepkowitz S. H., Goldfinger D. Treatment of babesiosis by red blood cell exchange in an HIV-positive, splenectomized patient. J Clin Apher. 1993;8(2):78–81. doi: 10.1002/jca.2920080205. [DOI] [PubMed] [Google Scholar]
  75. Maldonado R. A., Molina J., Payares G., Urbina J. A. Experimental chemotherapy with combinations of ergosterol biosynthesis inhibitors in murine models of Chagas' disease. Antimicrob Agents Chemother. 1993 Jun;37(6):1353–1359. doi: 10.1128/aac.37.6.1353. [DOI] [PMC free article] [PubMed] [Google Scholar]
  76. Marik P. E. Severe falciparum malaria: survival without exchange transfusion. Am J Trop Med Hyg. 1989 Dec;41(6):627–629. doi: 10.4269/ajtmh.1989.41.627. [DOI] [PubMed] [Google Scholar]
  77. Marshall R. J., Flanigan T. P. Paromomycin inhibits Cryptosporidium infection of a human enterocyte cell line. J Infect Dis. 1992 Apr;165(4):772–774. doi: 10.1093/infdis/165.4.772. [DOI] [PubMed] [Google Scholar]
  78. Masur H., Polis M. A., Tuazon C. U., Ogata-Arakaki D., Kovacs J. A., Katz D., Hilt D., Simmons T., Feuerstein I., Lundgren B. Salvage trial of trimetrexate-leucovorin for the treatment of cerebral toxoplasmosis in patients with AIDS. J Infect Dis. 1993 Jun;167(6):1422–1426. doi: 10.1093/infdis/167.6.1422. [DOI] [PubMed] [Google Scholar]
  79. McAuley J. B., Herwaldt B. L., Stokes S. L., Becher J. A., Roberts J. M., Michelson M. K., Juranek D. D. Diloxanide furoate for treating asymptomatic Entamoeba histolytica cyst passers: 14 years' experience in the United States. Clin Infect Dis. 1992 Sep;15(3):464–468. doi: 10.1093/clind/15.3.464. [DOI] [PubMed] [Google Scholar]
  80. McAuley J., Boyer K. M., Patel D., Mets M., Swisher C., Roizen N., Wolters C., Stein L., Stein M., Schey W. Early and longitudinal evaluations of treated infants and children and untreated historical patients with congenital toxoplasmosis: the Chicago Collaborative Treatment Trial. Clin Infect Dis. 1994 Jan;18(1):38–72. doi: 10.1093/clinids/18.1.38. [DOI] [PubMed] [Google Scholar]
  81. McCabe R., Chirurgi V. Issues in toxoplasmosis. Infect Dis Clin North Am. 1993 Sep;7(3):587–604. [PubMed] [Google Scholar]
  82. McMeeking A., Borkowsky W., Klesius P. H., Bonk S., Holzman R. S., Lawrence H. S. A controlled trial of bovine dialyzable leukocyte extract for cryptosporidiosis in patients with AIDS. J Infect Dis. 1990 Jan;161(1):108–112. doi: 10.1093/infdis/161.1.108. [DOI] [PubMed] [Google Scholar]
  83. Meshnick S. R., Yang Y. Z., Lima V., Kuypers F., Kamchonwongpaisan S., Yuthavong Y. Iron-dependent free radical generation from the antimalarial agent artemisinin (qinghaosu). Antimicrob Agents Chemother. 1993 May;37(5):1108–1114. doi: 10.1128/aac.37.5.1108. [DOI] [PMC free article] [PubMed] [Google Scholar]
  84. Miller K. D., Greenberg A. E., Campbell C. C. Treatment of severe malaria in the United States with a continuous infusion of quinidine gluconate and exchange transfusion. N Engl J Med. 1989 Jul 13;321(2):65–70. doi: 10.1056/NEJM198907133210201. [DOI] [PubMed] [Google Scholar]
  85. Miller K. D., Lobel H. O., Satriale R. F., Kuritsky J. N., Stern R., Campbell C. C. Severe cutaneous reactions among American travelers using pyrimethamine-sulfadoxine (Fansidar) for malaria prophylaxis. Am J Trop Med Hyg. 1986 May;35(3):451–458. doi: 10.4269/ajtmh.1986.35.451. [DOI] [PubMed] [Google Scholar]
  86. Miller L. H., Glew R. H., Wyler D. J., Howard W. A., Collins W. E., Contacos P. G., Neva F. A. Evaluation of clindamycin in combination with quinine against multidrug-resistant strains of Plasmodium falciparum. Am J Trop Med Hyg. 1974 Jul;23(4):565–569. doi: 10.4269/ajtmh.1974.23.565. [DOI] [PubMed] [Google Scholar]
  87. Milord F., Pépin J., Loko L., Ethier L., Mpia B. Efficacy and toxicity of eflornithine for treatment of Trypanosoma brucei gambiense sleeping sickness. Lancet. 1992 Sep 12;340(8820):652–655. doi: 10.1016/0140-6736(92)92180-n. [DOI] [PubMed] [Google Scholar]
  88. Mishra M., Biswas U. K., Jha D. N., Khan A. B. Amphotericin versus pentamidine in antimony-unresponsive kala-azar. Lancet. 1992 Nov 21;340(8830):1256–1257. doi: 10.1016/0140-6736(92)92952-c. [DOI] [PubMed] [Google Scholar]
  89. Moens F., De Wilde M., Ngato K. Essai de traitement au nifurtimox de la trypanosomiase humaine africaine. Ann Soc Belg Med Trop. 1984 Mar;64(1):37–43. [PubMed] [Google Scholar]
  90. Murphy T. V., Nelson J. D. Five v ten days' therapy with furazolidone for giardiasis. Am J Dis Child. 1983 Mar;137(3):267–270. doi: 10.1001/archpedi.1983.02140290053014. [DOI] [PubMed] [Google Scholar]
  91. Navin T. R., Arana B. A., Arana F. E., Berman J. D., Chajón J. F. Placebo-controlled clinical trial of sodium stibogluconate (Pentostam) versus ketoconazole for treating cutaneous leishmaniasis in Guatemala. J Infect Dis. 1992 Mar;165(3):528–534. doi: 10.1093/infdis/165.3.528. [DOI] [PubMed] [Google Scholar]
  92. Nord J., Ma P., DiJohn D., Tzipori S., Tacket C. O. Treatment with bovine hyperimmune colostrum of cryptosporidial diarrhea in AIDS patients. AIDS. 1990 Jun;4(6):581–584. doi: 10.1097/00002030-199006000-00015. [DOI] [PubMed] [Google Scholar]
  93. Norrby R., Eilard T., Svedhem A., Lycke E. Treatment of toxoplasmosis with trimethoprim-sulphamethoxazole. Scand J Infect Dis. 1975;7(1):72–75. doi: 10.3109/inf.1975.7.issue-1.13. [DOI] [PubMed] [Google Scholar]
  94. Nosten F., Luxemburger C., ter Kuile F. O., Woodrow C., Eh J. P., Chongsuphajaisiddhi T., White N. J. Treatment of multidrug-resistant Plasmodium falciparum malaria with 3-day artesunate-mefloquine combination. J Infect Dis. 1994 Oct;170(4):971–977. doi: 10.1093/infdis/170.4.971. [DOI] [PubMed] [Google Scholar]
  95. Nosten F., ter Kuile F., Chongsuphajaisiddhi T., Luxemburger C., Webster H. K., Edstein M., Phaipun L., Thew K. L., White N. J. Mefloquine-resistant falciparum malaria on the Thai-Burmese border. Lancet. 1991 May 11;337(8750):1140–1143. doi: 10.1016/0140-6736(91)92798-7. [DOI] [PubMed] [Google Scholar]
  96. Oren B., Schgurensky E., Ephros M., Tamir I., Raz R. Single-dose ornidazole versus seven-day metronidazole therapy of giardiasis in Kibbutzim children in Israel. Eur J Clin Microbiol Infect Dis. 1991 Nov;10(11):963–965. doi: 10.1007/BF02005454. [DOI] [PubMed] [Google Scholar]
  97. Orenstein J. M., Chiang J., Steinberg W., Smith P. D., Rotterdam H., Kotler D. P. Intestinal microsporidiosis as a cause of diarrhea in human immunodeficiency virus-infected patients: a report of 20 cases. Hum Pathol. 1990 May;21(5):475–481. doi: 10.1016/0046-8177(90)90003-n. [DOI] [PubMed] [Google Scholar]
  98. Pang L. W., Limsomwong N., Boudreau E. F., Singharaj P. Doxycycline prophylaxis for falciparum malaria. Lancet. 1987 May 23;1(8543):1161–1164. doi: 10.1016/s0140-6736(87)92141-6. [DOI] [PubMed] [Google Scholar]
  99. Pang L., Limsomwong N., Singharaj P. Prophylactic treatment of vivax and falciparum malaria with low-dose doxycycline. J Infect Dis. 1988 Nov;158(5):1124–1127. doi: 10.1093/infdis/158.5.1124. [DOI] [PubMed] [Google Scholar]
  100. Pedrol E., González-Clemente J. M., Gatell J. M., Mallolas J., Miró J. M., Graus F., Alvarez R., Mercader J. M., Berenguer J., Jiménez de Anta M. T. Central nervous system toxoplasmosis in AIDS patients: efficacy of an intermittent maintenance therapy. AIDS. 1990 Jun;4(6):511–517. doi: 10.1097/00002030-199006000-00003. [DOI] [PubMed] [Google Scholar]
  101. Pepin J., Milord F., Guern C., Mpia B., Ethier L., Mansinsa D. Trial of prednisolone for prevention of melarsoprol-induced encephalopathy in gambiense sleeping sickness. Lancet. 1989 Jun 3;1(8649):1246–1250. doi: 10.1016/s0140-6736(89)92340-4. [DOI] [PubMed] [Google Scholar]
  102. Pepin J., Milord F., Guern C., Schechter P. J. Difluoromethylornithine for arseno-resistant Trypanosoma brucei gambiense sleeping sickness. Lancet. 1987 Dec 19;2(8573):1431–1433. doi: 10.1016/s0140-6736(87)91131-7. [DOI] [PubMed] [Google Scholar]
  103. Pepin J., Milord F., Mpia B., Meurice F., Ethier L., DeGroof D., Bruneel H. An open clinical trial of nifurtimox for arseno-resistant Trypanosoma brucei gambiense sleeping sickness in central Zaire. Trans R Soc Trop Med Hyg. 1989 Jul-Aug;83(4):514–517. doi: 10.1016/0035-9203(89)90270-8. [DOI] [PubMed] [Google Scholar]
  104. Petersen C. Cryptosporidiosis in patients infected with the human immunodeficiency virus. Clin Infect Dis. 1992 Dec;15(6):903–909. doi: 10.1093/clind/15.6.903. [DOI] [PubMed] [Google Scholar]
  105. Pilla A. M., Rybak M. J., Chandrasekar P. H. Spiramycin in the treatment of cryptosporidiosis. Pharmacotherapy. 1987;7(5):188–190. doi: 10.1002/j.1875-9114.1987.tb04049.x. [DOI] [PubMed] [Google Scholar]
  106. Plettenberg A., Stoehr A., Stellbrink H. J., Albrecht H., Meigel W. A preparation from bovine colostrum in the treatment of HIV-positive patients with chronic diarrhea. Clin Investig. 1993 Jan;71(1):42–45. doi: 10.1007/BF00210962. [DOI] [PubMed] [Google Scholar]
  107. Popovsky M. A., Lindberg L. E., Syrek A. L., Page P. L. Prevalence of Babesia antibody in a selected blood donor population. Transfusion. 1988 Jan-Feb;28(1):59–61. doi: 10.1046/j.1537-2995.1988.28188127955.x. [DOI] [PubMed] [Google Scholar]
  108. Porter S. B., Sande M. A. Toxoplasmosis of the central nervous system in the acquired immunodeficiency syndrome. N Engl J Med. 1992 Dec 3;327(23):1643–1648. doi: 10.1056/NEJM199212033272306. [DOI] [PubMed] [Google Scholar]
  109. Portnoy D., Whiteside M. E., Buckley E., 3rd, MacLeod C. L. Treatment of intestinal cryptosporidiosis with spiramycin. Ann Intern Med. 1984 Aug;101(2):202–204. doi: 10.7326/0003-4819-101-2-202. [DOI] [PubMed] [Google Scholar]
  110. Powell S. J., MacLeod I., Wilmot A. J., Elsdon-Dew R. Metronidazole in amoebic dysentery and amoebic liver abscess. Lancet. 1966 Dec 17;2(7477):1329–1331. doi: 10.1016/s0140-6736(66)92081-2. [DOI] [PubMed] [Google Scholar]
  111. Pépin J., Milord F., Meurice F., Ethier L., Loko L., Mpia B. High-dose nifurtimox for arseno-resistant Trypanosoma brucei gambiense sleeping sickness: an open trial in central Zaire. Trans R Soc Trop Med Hyg. 1992 May-Jun;86(3):254–256. doi: 10.1016/0035-9203(92)90298-q. [DOI] [PubMed] [Google Scholar]
  112. Quinn T. C., Mann J. M., Curran J. W., Piot P. AIDS in Africa: an epidemiologic paradigm. Science. 1986 Nov 21;234(4779):955–963. doi: 10.1126/science.3022379. [DOI] [PubMed] [Google Scholar]
  113. Raoult D., Soulayrol L., Toga B., Dumon H., Casanova P. Babesiosis, pentamidine, and cotrimoxazole. Ann Intern Med. 1987 Dec;107(6):944–944. doi: 10.7326/0003-4819-107-6-944_2. [DOI] [PubMed] [Google Scholar]
  114. Ravdin J. I., Skilogiannis J. In vitro susceptibilities of Entamoeba histolytica to azithromycin, CP-63,956, erythromycin, and metronidazole. Antimicrob Agents Chemother. 1989 Jun;33(6):960–962. doi: 10.1128/aac.33.6.960. [DOI] [PMC free article] [PubMed] [Google Scholar]
  115. Reacher M., Campbell C. C., Freeman J., Doberstyn E. B., Brandling-Bennett A. D. Drug therapy for Plasmodium falciparum malaria resistant to pyrimethamine-sulfadoxine (Fansidar). A study of alternate regimens in Eastern Thailand, 1980. Lancet. 1981 Nov 14;2(8255):1066–1069. doi: 10.1016/s0140-6736(81)91274-5. [DOI] [PubMed] [Google Scholar]
  116. Reed S. G. In vivo administration of recombinant IFN-gamma induces macrophage activation, and prevents acute disease, immune suppression, and death in experimental Trypanosoma cruzi infections. J Immunol. 1988 Jun 15;140(12):4342–4347. [PubMed] [Google Scholar]
  117. Rehg J. E. A comparison of anticryptosporidial activity of paromomycin with that of other aminoglycosides and azithromycin in immunosuppressed rats. J Infect Dis. 1994 Oct;170(4):934–938. doi: 10.1093/infdis/170.4.934. [DOI] [PubMed] [Google Scholar]
  118. Rehg J. E. Activity of azithromycin against cryptosporidia in immunosuppressed rats. J Infect Dis. 1991 Jun;163(6):1293–1296. doi: 10.1093/infdis/163.6.1293. [DOI] [PubMed] [Google Scholar]
  119. Rekg J. E., Hancock M. L., Woodmansee D. B. Anticryptosporidial activity of sulfadimethoxine. Antimicrob Agents Chemother. 1988 Dec;32(12):1907–1908. doi: 10.1128/aac.32.12.1907. [DOI] [PMC free article] [PubMed] [Google Scholar]
  120. Remington J. S., Vildé J. L. Clindamycin for toxoplasma encephalitis in AIDS. Lancet. 1991 Nov 2;338(8775):1142–1143. doi: 10.1016/0140-6736(91)91997-9. [DOI] [PubMed] [Google Scholar]
  121. Reubush T. K., 2nd, Cassaday P. B., Marsh H. J., Lisker S. A., Voorhees D. B., Mahoney E. B., Healy G. R. Human babesiosis on Nantucket Island. Clinical features. Ann Intern Med. 1977 Jan;86(1):6–9. doi: 10.7326/0003-4819-86-1-6. [DOI] [PubMed] [Google Scholar]
  122. Rieckmann K. H., Davis D. R., Hutton D. C. Plasmodium vivax resistance to chloroquine? Lancet. 1989 Nov 18;2(8673):1183–1184. doi: 10.1016/s0140-6736(89)91792-3. [DOI] [PubMed] [Google Scholar]
  123. Rolston K. V., Fainstein V., Bodey G. P. Intestinal crytosporidiosis treated with eflornithine: a prospective study among patients with AIDS. J Acquir Immune Defic Syndr. 1989;2(5):426–430. [PubMed] [Google Scholar]
  124. Rosenthal P. J., Nelson R. G. Isolation and characterization of a cysteine proteinase gene of Plasmodium falciparum. Mol Biochem Parasitol. 1992 Mar;51(1):143–152. doi: 10.1016/0166-6851(92)90209-3. [DOI] [PubMed] [Google Scholar]
  125. Rowin K. S., Tanowitz H. B., Wittner M. Therapy of experimental babesiosis. Ann Intern Med. 1982 Oct;97(4):556–558. doi: 10.7326/0003-4819-97-4-556. [DOI] [PubMed] [Google Scholar]
  126. Ruebush T. K., 2nd, Rubin R. H., Wolpow E. R., Cassaday P. B., Schultz M. G. Neurologic complications following the treatment of human Babesia microti infection with diminazene aceturate. Am J Trop Med Hyg. 1979 Mar;28(2):184–189. doi: 10.4269/ajtmh.1979.28.184. [DOI] [PubMed] [Google Scholar]
  127. Ruf B., Schürmann D., Pohle H. D. Failure of clarithromycin in preventing toxoplasmic encephalitis in AIDS patients. J Acquir Immune Defic Syndr. 1992;5(5):530–531. doi: 10.1097/00126334-199205000-00018. [DOI] [PubMed] [Google Scholar]
  128. Saenz R. E., Paz H., Berman J. D. Efficacy of ketoconazole against Leishmania braziliensis panamensis cutaneous leishmaniasis. Am J Med. 1990 Aug;89(2):147–155. doi: 10.1016/0002-9343(90)90292-l. [DOI] [PubMed] [Google Scholar]
  129. Schmuñis G. A. Trypanosoma cruzi, the etiologic agent of Chagas' disease: status in the blood supply in endemic and nonendemic countries. Transfusion. 1991 Jul-Aug;31(6):547–557. doi: 10.1046/j.1537-2995.1991.31691306255.x. [DOI] [PubMed] [Google Scholar]
  130. Seaberg L. S., Parquette A. R., Gluzman I. Y., Phillips G. W., Jr, Brodasky T. F., Krogstad D. J. Clindamycin activity against chloroquine-resistant Plasmodium falciparum. J Infect Dis. 1984 Dec;150(6):904–911. doi: 10.1093/infdis/150.6.904. [DOI] [PubMed] [Google Scholar]
  131. Seaman J., Pryce D., Sondorp H. E., Moody A., Bryceson A. D., Davidson R. N. Epidemic visceral leishmaniasis in Sudan: a randomized trial of aminosidine plus sodium stibogluconate versus sodium stibogluconate alone. J Infect Dis. 1993 Sep;168(3):715–720. doi: 10.1093/infdis/168.3.715. [DOI] [PubMed] [Google Scholar]
  132. Shadduck J. A. Effect of fumagillin on in vitro multiplication of Encephalitozoon cuniculi. J Protozool. 1980 May;27(2):202–208. doi: 10.1111/j.1550-7408.1980.tb04681.x. [DOI] [PubMed] [Google Scholar]
  133. Simon D., Weiss L. M., Tanowitz H. B., Cali A., Jones J., Wittner M. Light microscopic diagnosis of human microsporidiosis and variable response to octreotide. Gastroenterology. 1991 Jan;100(1):271–273. doi: 10.1016/0016-5085(91)90613-p. [DOI] [PubMed] [Google Scholar]
  134. Simon M., Shookhoff H. B., Terner H., Weingarten B., Parker J. G. Paromomycin in the treatment of intestinal amebiasis; a short course of therapy. Am J Gastroenterol. 1967 Dec;48(6):504–511. [PubMed] [Google Scholar]
  135. Sjoerdsma A., Schechter P. J. Chemotherapeutic implications of polyamine biosynthesis inhibition. Clin Pharmacol Ther. 1984 Mar;35(3):287–300. doi: 10.1038/clpt.1984.33. [DOI] [PubMed] [Google Scholar]
  136. Smith P. D., Lane H. C., Gill V. J., Manischewitz J. F., Quinnan G. V., Fauci A. S., Masur H. Intestinal infections in patients with the acquired immunodeficiency syndrome (AIDS). Etiology and response to therapy. Ann Intern Med. 1988 Mar;108(3):328–333. doi: 10.7326/0003-4819-108-3-328. [DOI] [PubMed] [Google Scholar]
  137. Smith R. P., Evans A. T., Popovsky M., Mills L., Spielman A. Transfusion-acquired babesiosis and failure of antibiotic treatment. JAMA. 1986 Nov 21;256(19):2726–2727. [PubMed] [Google Scholar]
  138. Soto-Mancipe J., Grogl M., Berman J. D. Evaluation of pentamidine for the treatment of cutaneous leishmaniasis in Colombia. Clin Infect Dis. 1993 Mar;16(3):417–425. doi: 10.1093/clind/16.3.417. [DOI] [PubMed] [Google Scholar]
  139. Soto J., Buffet P., Grogl M., Berman J. Successful treatment of Colombian cutaneous leishmaniasis with four injections of pentamidine. Am J Trop Med Hyg. 1994 Jan;50(1):107–111. doi: 10.4269/ajtmh.1994.50.107. [DOI] [PubMed] [Google Scholar]
  140. Speelman P. Single-dose tinidazole for the treatment of giardiasis. Antimicrob Agents Chemother. 1985 Feb;27(2):227–229. doi: 10.1128/aac.27.2.227. [DOI] [PMC free article] [PubMed] [Google Scholar]
  141. Squires K. E., Rosenkaimer F., Sherwood J. A., Forni A. L., Were J. B., Murray H. W. Immunochemotherapy for visceral leishmaniasis: a controlled pilot trial of antimony versus antimony plus interferon-gamma. Am J Trop Med Hyg. 1993 May;48(5):666–669. doi: 10.4269/ajtmh.1993.48.666. [DOI] [PubMed] [Google Scholar]
  142. Sullam P. M., Slutkin G., Gottlieb A. B., Mills J. Paromomycin therapy of endemic amebiasis in homosexual men. Sex Transm Dis. 1986 Jul-Sep;13(3):151–155. doi: 10.1097/00007435-198607000-00007. [DOI] [PubMed] [Google Scholar]
  143. Taelman H., Schechter P. J., Marcelis L., Sonnet J., Kazyumba G., Dasnoy J., Haegele K. D., Sjoerdsma A., Wery M. Difluoromethylornithine, an effective new treatment of Gambian trypanosomiasis. Results in five patients. Am J Med. 1987 Mar 23;82(3 Spec No):607–614. doi: 10.1016/0002-9343(87)90107-0. [DOI] [PubMed] [Google Scholar]
  144. Teixeira A. R., Córdoba J. C., Souto Maior I., Solórzano E. Chagas' disease: lymphoma growth in rabbits treated with Benznidazole. Am J Trop Med Hyg. 1990 Aug;43(2):146–158. doi: 10.4269/ajtmh.1990.43.146. [DOI] [PubMed] [Google Scholar]
  145. Teixeira A. R., Silva R., Cunha Neto E., Santana J. M., Rizzo L. V. Malignant, non-Hodgkin's lymphomas in Trypanosoma cruzi-infected rabbits treated with nitroarenes. J Comp Pathol. 1990 Jul;103(1):37–48. doi: 10.1016/s0021-9975(08)80133-8. [DOI] [PubMed] [Google Scholar]
  146. Thakur C. P., Kumar M., Kumar P., Mishra B. N., Pandey A. K. Rationalisation of regimens of treatment of kala-azar with sodium stibogluconate in India: a randomised study. Br Med J (Clin Res Ed) 1988 Jun 4;296(6636):1557–1561. doi: 10.1136/bmj.296.6636.1557. [DOI] [PMC free article] [PubMed] [Google Scholar]
  147. Thakur C. P., Kumar M., Pandey A. K. Comparison of regimes of treatment of antimony-resistant kala-azar patients: a randomized study. Am J Trop Med Hyg. 1991 Oct;45(4):435–441. doi: 10.4269/ajtmh.1991.45.435. [DOI] [PubMed] [Google Scholar]
  148. Thakur C. P., Olliaro P., Gothoskar S., Bhowmick S., Choudhury B. K., Prasad S., Kumar M., Verma B. B. Treatment of visceral leishmaniasis (kala-azar) with aminosidine (= paromomycin)-antimonial combinations, a pilot study in Bihar, India. Trans R Soc Trop Med Hyg. 1992 Nov-Dec;86(6):615–616. doi: 10.1016/0035-9203(92)90150-b. [DOI] [PubMed] [Google Scholar]
  149. Thakur C. P., Sinha G. P., Sharma V., Pandey A. K., Kumar M., Verma B. B. Evaluation of amphotericin B as a first line drug in comparison to sodium stibogluconate in the treatment of fresh cases of kala-azar. Indian J Med Res. 1993 Jul;97:170–175. [PubMed] [Google Scholar]
  150. Torre-Cisneros J., Villanueva J. L., Kindelan J. M., Jurado R., Sanchez-Guijo P. Successful treatment of antimony-resistant visceral leishmaniasis with liposomal amphotericin B in patients infected with human immunodeficiency virus. Clin Infect Dis. 1993 Oct;17(4):625–627. doi: 10.1093/clinids/17.4.625. [DOI] [PubMed] [Google Scholar]
  151. Ungar B. L., Ward D. J., Fayer R., Quinn C. A. Cessation of Cryptosporidium-associated diarrhea in an acquired immunodeficiency syndrome patient after treatment with hyperimmune bovine colostrum. Gastroenterology. 1990 Feb;98(2):486–489. doi: 10.1016/0016-5085(90)90842-o. [DOI] [PubMed] [Google Scholar]
  152. Upcroft J. A., Upcroft P., Boreham P. F. Drug resistance in Giardia intestinalis. Int J Parasitol. 1990 Jul;20(4):489–496. doi: 10.1016/0020-7519(90)90196-t. [DOI] [PubMed] [Google Scholar]
  153. Urbina J. A., Lazardi K., Marchan E., Visbal G., Aguirre T., Piras M. M., Piras R., Maldonado R. A., Payares G., de Souza W. Mevinolin (lovastatin) potentiates the antiproliferative effects of ketoconazole and terbinafine against Trypanosoma (Schizotrypanum) cruzi: in vitro and in vivo studies. Antimicrob Agents Chemother. 1993 Mar;37(3):580–591. doi: 10.1128/aac.37.3.580. [DOI] [PMC free article] [PubMed] [Google Scholar]
  154. Van Nieuwenhove S., Schechter P. J., Declercq J., Boné G., Burke J., Sjoerdsma A. Treatment of gambiense sleeping sickness in the Sudan with oral DFMO (DL-alpha-difluoromethylornithine), an inhibitor of ornithine decarboxylase; first field trial. Trans R Soc Trop Med Hyg. 1985;79(5):692–698. doi: 10.1016/0035-9203(85)90195-6. [DOI] [PubMed] [Google Scholar]
  155. Van Voorhis W. C. Therapy and prophylaxis of systemic protozoan infections. Drugs. 1990 Aug;40(2):176–202. doi: 10.2165/00003495-199040020-00002. [DOI] [PubMed] [Google Scholar]
  156. Viotti R., Vigliano C., Armenti H., Segura E. Treatment of chronic Chagas' disease with benznidazole: clinical and serologic evolution of patients with long-term follow-up. Am Heart J. 1994 Jan;127(1):151–162. doi: 10.1016/0002-8703(94)90521-5. [DOI] [PubMed] [Google Scholar]
  157. Wali J. P., Aggarwal P., Gupta U., Saluja S., Singh S. Ketoconazole in the treatment of antimony- and pentamidine-resistant kala-azar. J Infect Dis. 1992 Jul;166(1):215–216. doi: 10.1093/infdis/166.1.215. [DOI] [PubMed] [Google Scholar]
  158. Warrell D. A., Looareesuwan S., Warrell M. J., Kasemsarn P., Intaraprasert R., Bunnag D., Harinasuta T. Dexamethasone proves deleterious in cerebral malaria. A double-blind trial in 100 comatose patients. N Engl J Med. 1982 Feb 11;306(6):313–319. doi: 10.1056/NEJM198202113060601. [DOI] [PubMed] [Google Scholar]
  159. Weber R., Bryan R. T., Schwartz D. A., Owen R. L. Human microsporidial infections. Clin Microbiol Rev. 1994 Oct;7(4):426–461. doi: 10.1128/cmr.7.4.426. [DOI] [PMC free article] [PubMed] [Google Scholar]
  160. Weinrauch L., Livshin R., Even-Paz Z., El-On J. Efficacy of ketoconazole in cutaneous leishmaniasis. Arch Dermatol Res. 1983;275(5):353–354. doi: 10.1007/BF00417211. [DOI] [PubMed] [Google Scholar]
  161. Weiss L. M., Wittner M., Wasserman S., Oz H. S., Retsema J., Tanowitz H. B. Efficacy of azithromycin for treating Babesia microti infection in the hamster model. J Infect Dis. 1993 Nov;168(5):1289–1292. doi: 10.1093/infdis/168.5.1289. [DOI] [PubMed] [Google Scholar]
  162. White N. J., Looareesuwan S., Warrell D. A., Chongsuphajaisiddhi T., Bunnag D., Harinasuta T. Quinidine in falciparum malaria. Lancet. 1981 Nov 14;2(8255):1069–1071. doi: 10.1016/s0140-6736(81)91275-7. [DOI] [PubMed] [Google Scholar]
  163. Wittenberg D. F., Miller N. M., van den Ende J. Spiramycin is not effective in treating cryptosporidium diarrhea in infants: results of a double-blind randomized trial. J Infect Dis. 1989 Jan;159(1):131–132. doi: 10.1093/infdis/159.1.131. [DOI] [PubMed] [Google Scholar]
  164. Wittner M., Rowin K. S., Tanowitz H. B., Hobbs J. F., Saltzman S., Wenz B., Hirsch R., Chisholm E., Healy G. R. Successful chemotherapy of transfusion babesiosis. Ann Intern Med. 1982 May;96(5):601–604. doi: 10.7326/0003-4819-96-5-601. [DOI] [PubMed] [Google Scholar]
  165. Wolfe M. S. Giardiasis. JAMA. 1975 Sep 29;233(13):1362–1365. [PubMed] [Google Scholar]
  166. Wolfe M. S. Giardiasis. Clin Microbiol Rev. 1992 Jan;5(1):93–100. doi: 10.1128/cmr.5.1.93. [DOI] [PMC free article] [PubMed] [Google Scholar]
  167. Wolfe M. S. Nondysenteric intestinal amebiasis. Treatment with diloxanide furoate. JAMA. 1973 Jun 18;224(12):1601–1604. [PubMed] [Google Scholar]
  168. al-Fouzan A. S., al Saleh Q. A., Najem N. M., Rostom A. I. Cutaneous leishmaniasis in Kuwait. Clinical experience with itraconazole. Int J Dermatol. 1991 Jul;30(7):519–521. doi: 10.1111/j.1365-4362.1991.tb04878.x. [DOI] [PubMed] [Google Scholar]
  169. al-Waili N. S., al-Waili B. H., Saloom K. Y. Therapeutic use of mebendazole in giardial infections. Trans R Soc Trop Med Hyg. 1988;82(3):438–438. doi: 10.1016/0035-9203(88)90156-3. [DOI] [PubMed] [Google Scholar]
  170. di Martino L., Nocerino A., Mantovani M. P. Mebendazole in giardial infections: confirmation of the failure of this treatment. Trans R Soc Trop Med Hyg. 1991 Jul-Aug;85(4):557–558. doi: 10.1016/0035-9203(91)90264-y. [DOI] [PubMed] [Google Scholar]

Articles from Clinical Microbiology Reviews are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES